Integer (ITGR) Projected to Post Quarterly Earnings on Thursday

Integer (NYSE:ITGR) is expected to issue its Q3 2025 results before the market opens on Thursday, October 23rd. Analysts expect the company to announce earnings of $1.68 per share and revenue of $466.4510 million for the quarter. Integer has set its FY 2025 guidance at 6.250-6.510 EPS.Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Thursday, October 23, 2025 at 9:00 AM ET.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, July 24th. The medical equipment provider reported $1.55 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.02). The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $464.37 million. Integer had a return on equity of 12.27% and a net margin of 4.61%.The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.30 earnings per share. On average, analysts expect Integer to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Integer Stock Up 2.4%

Shares of ITGR opened at $107.38 on Tuesday. The company has a market capitalization of $3.76 billion, a PE ratio of 47.30, a PEG ratio of 0.83 and a beta of 0.97. The company has a current ratio of 3.41, a quick ratio of 2.18 and a debt-to-equity ratio of 0.72. The stock’s 50-day moving average price is $104.95 and its two-hundred day moving average price is $113.00. Integer has a 12 month low of $99.54 and a 12 month high of $146.36.

Analyst Ratings Changes

ITGR has been the topic of several research analyst reports. Wall Street Zen upgraded Integer from a “hold” rating to a “buy” rating in a research report on Saturday, August 30th. Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research report on Wednesday, October 8th. Wells Fargo & Company cut their target price on Integer from $152.00 to $132.00 and set an “overweight” rating on the stock in a research report on Friday, July 25th. Raymond James Financial cut their target price on Integer from $150.00 to $143.00 and set an “outperform” rating on the stock in a research report on Friday, July 25th. Finally, Truist Financial cut their target price on Integer from $137.00 to $121.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $137.29.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its stake in Integer by 8.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,543 shares of the medical equipment provider’s stock worth $312,000 after buying an additional 188 shares during the period. State of Wyoming acquired a new position in Integer during the 2nd quarter worth approximately $233,000. Public Sector Pension Investment Board raised its stake in Integer by 11.8% during the 2nd quarter. Public Sector Pension Investment Board now owns 118,933 shares of the medical equipment provider’s stock worth $14,625,000 after buying an additional 12,551 shares during the period. FORA Capital LLC acquired a new position in Integer during the 2nd quarter worth approximately $535,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Integer by 74.7% in the second quarter. Tower Research Capital LLC TRC now owns 3,832 shares of the medical equipment provider’s stock worth $471,000 after purchasing an additional 1,639 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.